Literature DB >> 30994035

Towards a standard MRI protocol for multiple sclerosis across the UK.

Klaus Schmierer1,2, Thomas Campion3, Audrey Sinclair4, Wim van Hecke5, Paul M Matthews6, Mike P Wattjes7,8.   

Abstract

Multiple sclerosis is a chronic inflammatory demyelinating and degenerative disease of the central nervous system. It is the most common non-traumatic cause of chronic disability in young adults. An early and accurate diagnosis, and effective disease modifying treatment are key elements of optimum care for people with MS (pwMS). MRI has become a critical tool to confirm the presence of dissemination in space and time of lesions characteristic of inflammatory demyelination, a cornerstone of MS diagnosis, over and above exclusion of numerous differential diagnoses. In the modern era of early and highly effective DMT, follow-up of pwMS also relies heavily on MRI, to both confirm efficacy and for pharmacovigilance. Since criteria for MS rely heavily on MRI, an agreed standardized acquisition and reporting protocol enabling efficient and equitable application across the UK is desirable. Following a recent meeting of MS experts in London (UK), we make recommendations for a standardized UK MRI protocol that captures the diagnostic phase as well as monitoring for safety and treatment efficacy once the diagnosis is established. Our views take into account issues arising from the (repeated) use of contrast agents as well as the advent of (semi-) automated tools to further optimize disease monitoring in pwMS.

Entities:  

Mesh:

Year:  2019        PMID: 30994035      PMCID: PMC6732926          DOI: 10.1259/bjr.20180926

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  13 in total

Review 1.  Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients.

Authors:  Mike P Wattjes; Àlex Rovira; David Miller; Tarek A Yousry; Maria P Sormani; Maria P de Stefano; Mar Tintoré; Cristina Auger; Carmen Tur; Massimo Filippi; Maria A Rocca; Franz Fazekas; Ludwig Kappos; Chris Polman
Journal:  Nat Rev Neurol       Date:  2015-09-15       Impact factor: 42.937

Review 2.  No Evident Disease Activity-More Than a Risky Ambition?

Authors:  Benjamin Meir Jacobs; Gavin Giovannoni; Klaus Schmierer
Journal:  JAMA Neurol       Date:  2018-07-01       Impact factor: 18.302

3.  Computer-Aided Detection Can Bridge the Skill Gap in Multiple Sclerosis Monitoring.

Authors:  Ariel Dahan; Wayland Wang; Frank Gaillard
Journal:  J Am Coll Radiol       Date:  2017-07-29       Impact factor: 5.532

4.  Improved detection of active multiple sclerosis lesions: 3D subtraction imaging.

Authors:  Bastiaan Moraal; Mike P Wattjes; Jeroen J G Geurts; Dirk L Knol; Ronald A van Schijndel; Petra J W Pouwels; Hugo Vrenken; Frederik Barkhof
Journal:  Radiology       Date:  2010-04       Impact factor: 11.105

5.  Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis.

Authors:  A Traboulsee; J H Simon; L Stone; E Fisher; D E Jones; A Malhotra; S D Newsome; J Oh; D S Reich; N Richert; K Rammohan; O Khan; E-W Radue; C Ford; J Halper; D Li
Journal:  AJNR Am J Neuroradiol       Date:  2015-11-12       Impact factor: 3.825

6.  Automatic segmentation and volumetry of multiple sclerosis brain lesions from MR images.

Authors:  Saurabh Jain; Diana M Sima; Annemie Ribbens; Melissa Cambron; Anke Maertens; Wim Van Hecke; Johan De Mey; Frederik Barkhof; Martijn D Steenwijk; Marita Daams; Frederik Maes; Sabine Van Huffel; Hugo Vrenken; Dirk Smeets
Journal:  Neuroimage Clin       Date:  2015-05-16       Impact factor: 4.881

7.  Incidence and prevalence of multiple sclerosis in the UK 1990-2010: a descriptive study in the General Practice Research Database.

Authors:  I S Mackenzie; S V Morant; G A Bloomfield; T M MacDonald; J O'Riordan
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-09-19       Impact factor: 10.154

Review 8.  Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society.

Authors:  M Vågberg; M Axelsson; R Birgander; J Burman; C Cananau; Y Forslin; T Granberg; M Gunnarsson; A von Heijne; L Jönsson; V D Karrenbauer; E-M Larsson; T Lindqvist; J Lycke; L Lönn; E Mentesidou; S Müller; P Nilsson; F Piehl; A Svenningsson; M Vrethem; J Wikström
Journal:  Acta Neurol Scand       Date:  2016-08-24       Impact factor: 3.209

Review 9.  Infectious Complications of Multiple Sclerosis Therapies: Implications for Screening, Prophylaxis, and Management.

Authors:  David J Epstein; Jeffrey Dunn; Stan Deresinski
Journal:  Open Forum Infect Dis       Date:  2018-07-16       Impact factor: 3.835

10.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

View more
  2 in total

1.  Diagnosis and management of multiple sclerosis: MRI in clinical practice.

Authors:  Valentina Tomassini; Audrey Sinclair; Vijay Sawlani; James Overell; Owen R Pearson; Julie Hall; Joe Guadagno
Journal:  J Neurol       Date:  2020-05-29       Impact factor: 4.849

2.  Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients.

Authors:  Kimberley Allen-Philbey; Stefania De Trane; Zhifeng Mao; Cesar Álvarez-González; Joela Mathews; Amy MacDougall; Andrea Stennett; Xia Zhou; Ozlem Yildiz; Ashok Adams; Lucia Bianchi; Camilla Blain; Christine Chapman; Karen Chung; Cris S Constantinescu; Catherine Dalton; Rachel A Farrell; Leonora Fisniku; Helen Ford; Bruno Gran; Jeremy Hobart; Zhaleh Khaleeli; Miriam Mattoscio; Sue Pavitt; Owen Pearson; Luca Peruzzotti-Jametti; Antonio Scalfari; Basil Sharrack; Eli Silber; Emma C Tallantyre; Stewart Webb; Benjamin P Turner; Monica Marta; Sharmilee Gnanapavan; Gunnar Juliusson; Gavin Giovannoni; David Baker; Klaus Schmierer
Journal:  Ther Adv Neurol Disord       Date:  2021-11-25       Impact factor: 6.570

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.